The Department of Commerce's Bureau of Industry and Security (BIS) has released a crucial notice detailing how certain specialty pharmaceuticals and their ingredients can receive zero ad valorem tariff rates. This action stems directly from President Trump's Proclamation 11020, issued on April 2, 2026, which found that imports of pharmaceuticals and associated ingredients threatened national security under Section 232 of the Trade Expansion Act of 1962. While the proclamation initially imposed a 100 percent ad valorem tariff on certain patented pharmaceuticals, this new guidance outlines significant exemptions designed to safeguard public health and maintain access to vital medicines.
The Basis for Pharmaceutical Tariffs and Exemptions
President Trump's Proclamation 11020 followed a determination by the Secretary of Commerce that reliance on foreign pharmaceutical imports posed a national security risk. This led to the imposition of substantial tariffs on patented pharmaceuticals and ingredients. Notably, generic pharmaceutical products and ingredients were explicitly excluded from these tariffs. Additionally, companies that entered into Commerce-approved onshoring agreements also received different tariff rates, signaling an effort to encourage domestic manufacturing.
However, Proclamation 11020 also included a provision, clause 3(d), allowing for a zero ad valorem tariff rate on specific categories of specialty pharmaceuticals and associated ingredients. This new notice from BIS provides the operational framework for this critical carve-out. The goal is to ensure that while broader national security concerns are addressed, access to essential, often life-saving, medications remains unburdened by these tariffs.
Defining Specialty Pharmaceuticals for Zero Tariff Eligibility
The notice meticulously defines the types of pharmaceutical products eligible for the zero tariff rate. These definitions, developed in consultation with the Food and Drug Administration (FDA) and the U.S. Department of Agriculture Center for Veterinary Biologics, are specific to Proclamation 11020. The eligible categories include:
-
Orphan drugs: Those designated for rare diseases or conditions.
-
Nuclear medicines: Drugs containing radioactive substances used for diagnosis or therapy.
-
Plasma derived therapies: Biological products sourced from human blood or plasma.
-
Fertility drugs: Medications used in the treatment of infertility.
-
Cell therapy products: Biological products involving cellular immunotherapy or cellular cancer vaccines.
-
Gene therapy products: Biological products designed to modify gene expression or alter living cells for therapeutic use.
-
Antibody drug conjugates: Combination products linking a small-molecule drug to an antibody.
-
Medical countermeasures: Products against chemical, biological, radiological, and nuclear (CBRN) threats.
-
Animal healthcare products: Articles for diagnosis, treatment, or prevention of animal diseases, including biologics.
These definitions encompass both investigational drugs and FDA-approved or authorized drugs, ensuring broad coverage for innovation and access.
Dual Pathways to Zero Tariffs
For these specialty pharmaceuticals to qualify for the zero tariff rate, one of two conditions must be met, as directed by Proclamation 11020:
-
Jurisdictional Eligibility: The products must originate from a jurisdiction that has a current or forthcoming trade and security framework agreement, as referenced in President Trump's Executive Order 14346 of September 5, 2025. The notice provides an explicit list of these eligible jurisdictions, including Argentina, Bangladesh, Cambodia, Ecuador, El Salvador, the European Union, Guatemala, India, Indonesia, Japan, Jordan, Malaysia, North Macedonia, the Republic of Korea, Switzerland and Liechtenstein, Taiwan, Thailand, the United Kingdom, and Vietnam.
-
Urgent U.S. Health Need: If a product does not originate from an eligible jurisdiction, it can still qualify for zero tariffs if the Secretary of Commerce, in consultation with the U.S. Trade Representative (USTR) and the Secretary of Health and Human Services (HHS), determines that it meets an urgent U.S. health need. This pathway highlights a recognition that critical medical necessity can override tariff considerations.
Procedures for Urgent Health Need Applications
The notice details the process for companies to seek Commerce Department approval based on an urgent U.S. health need. Companies are instructed to submit requests electronically to BIS, providing comprehensive information. This includes organizational details, specific product identification (including HTSUS classification, active ingredients, and category), and a robust rationale justifying the urgent health need. The rationale should address factors such as the disease treated, the availability and assessment of alternative therapies, the number of U.S. patients who use the product, and its availability in other jurisdictions. These submissions are accepted on an ongoing basis, and each request will undergo an individual, fact-specific, and company-specific review by Commerce, USTR, and HHS.
Implications for Industry and Public Health
This new guidance provides much-needed clarity for pharmaceutical companies navigating the complex tariff landscape established by Proclamation 11020. By exempting critical specialty pharmaceuticals under specific conditions, the policy attempts to mitigate potential negative impacts on patient access to innovative and essential treatments, particularly for rare diseases, emergencies, and specialized medical needs. The inclusion of an 'urgent U.S. health need' pathway demonstrates a flexible approach, allowing for unforeseen medical demands to be addressed without the burden of tariffs.
However, the administrative requirements for seeking exemptions, particularly for urgent health needs, place a significant burden on companies. The need for detailed submissions and the multi-agency review process suggest a rigorous gatekeeping mechanism. The listed jurisdictions reflect existing or planned trade and security alliances, underscoring the interplay between trade policy, national security, and public health. This targeted approach seeks to fortify the U.S. pharmaceutical supply chain by reducing reliance on potentially adversarial sources, while simultaneously ensuring that the most vulnerable patients and critical medical interventions are protected.
